<Suppliers Price>

SB-1317

Names

[ CAS No. ]:
1204918-72-8

[ Name ]:
SB-1317

[Synonym ]:
(16E)-14-Methyl-20-oxa-5,7,14,27-tetraazatetracyclo[19.3.1.1.1]heptacosa-1(25),2(27),3,5,8(26),9,11,16,21,23-decaene
20-Oxa-5,7,14,27-tetraazatetracyclo[19.3.1.1.1]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 14-methyl-, (16E)-
SB-1317

Biological Activity

[Description]:

Zotiraciclib (TG02) is an orally active potent inhibitor of CDK2, JAK2 and FLT3 with IC50 values of 13, 73, and 56 nM, respectively. Zotiraciclib can be used for the research of advanced leukemias and multiple myeloma[1][2].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> JAK/STAT Signaling >> JAK
Signaling Pathways >> Epigenetics >> JAK
Signaling Pathways >> Stem Cell/Wnt >> JAK
Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FLT3
Signaling Pathways >> Cell Cycle/DNA Damage >> CDK

[References]

[1]. William AD, et al. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer. J Med Chem. 2012 Jan 12;55(1):169-96.  

[2]. Pasha MK, et al. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.  

Chemical & Physical Properties

[ Density]:
1.1±0.1 g/cm3

[ Boiling Point ]:
577.1±60.0 °C at 760 mmHg

[ Molecular Formula ]:
C23H24N4O

[ Molecular Weight ]:
372.46

[ Flash Point ]:
302.8±32.9 °C

[ Exact Mass ]:
372.195007

[ LogP ]:
4.76

[ Vapour Pressure ]:
0.0±1.6 mmHg at 25°C

[ Index of Refraction ]:
1.577

Related Compounds